Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

140 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Trials and tribulations of noninferiority: the ximelagatran experience.
Albers GW, Diener HC, Frison L, Grind M, Horrow J, Nevinson M, Olsson SB, Partridge S, Petersen P, Vahanian A, Halperin JL; Executive Steering Committee for the SPORTIF III and V Investigators. Albers GW, et al. Among authors: horrow j. J Am Coll Cardiol. 2006 Sep 5;48(5):1058; author reply 1059. doi: 10.1016/j.jacc.2006.06.004. Epub 2006 Aug 17. J Am Coll Cardiol. 2006. PMID: 16949503 Free article. No abstract available.
Risks and benefits of combining aspirin with anticoagulant therapy in patients with atrial fibrillation: an exploratory analysis of stroke prevention using an oral thrombin inhibitor in atrial fibrillation (SPORTIF) trials.
Flaker GC, Gruber M, Connolly SJ, Goldman S, Chaparro S, Vahanian A, Halinen MO, Horrow J, Halperin JL; SPORTIF Investigators. Flaker GC, et al. Among authors: horrow j. Am Heart J. 2006 Nov;152(5):967-73. doi: 10.1016/j.ahj.2006.06.024. Am Heart J. 2006. PMID: 17070169
Comparison of bleeding in patients with nonvalvular atrial fibrillation treated with ximelagatran or warfarin: assessment of incidence, case-fatality rate, time course and sites of bleeding, and risk factors for bleeding.
Douketis JD, Arneklev K, Goldhaber SZ, Spandorfer J, Halperin F, Horrow J. Douketis JD, et al. Among authors: horrow j. Arch Intern Med. 2006 Apr 24;166(8):853-9. doi: 10.1001/archinte.166.8.853. Arch Intern Med. 2006. PMID: 16636210 Clinical Trial.
Cardiovascular events in acute coronary syndrome patients with peripheral arterial disease treated with ticagrelor compared with clopidogrel: Data from the PLATO Trial.
Patel MR, Becker RC, Wojdyla DM, Emanuelsson H, Hiatt WR, Horrow J, Husted S, Mahaffey KW, Steg PG, Storey RF, Wallentin L, James SK. Patel MR, et al. Among authors: horrow j. Eur J Prev Cardiol. 2015 Jun;22(6):734-42. doi: 10.1177/2047487314533215. Epub 2014 May 15. Eur J Prev Cardiol. 2015. PMID: 24830710 Clinical Trial.
Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial.
Becker RC, Bassand JP, Budaj A, Wojdyla DM, James SK, Cornel JH, French J, Held C, Horrow J, Husted S, Lopez-Sendon J, Lassila R, Mahaffey KW, Storey RF, Harrington RA, Wallentin L. Becker RC, et al. Among authors: horrow j. Eur Heart J. 2011 Dec;32(23):2933-44. doi: 10.1093/eurheartj/ehr422. Epub 2011 Nov 16. Eur Heart J. 2011. PMID: 22090660 Clinical Trial.
Prior smoking status, clinical outcomes, and the comparison of ticagrelor with clopidogrel in acute coronary syndromes-insights from the PLATelet inhibition and patient Outcomes (PLATO) trial.
Cornel JH, Becker RC, Goodman SG, Husted S, Katus H, Santoso A, Steg G, Storey RF, Vintila M, Sun JL, Horrow J, Wallentin L, Harrington R, James S. Cornel JH, et al. Among authors: horrow j. Am Heart J. 2012 Sep;164(3):334-342.e1. doi: 10.1016/j.ahj.2012.06.005. Epub 2012 Jul 26. Am Heart J. 2012. PMID: 22980299 Clinical Trial.
140 results